Fredun Pharmaceuticals L
NSE: FREDUN · Pharmaceuticals · sector
₹1,365.50NSE close 2026-10-26
Key numbers
Market cap₹753 cr
Price₹1,365.50
52w high / low₹1,665 / ₹1,195
P/E16.4xSector median 27.9x
P/B2.7xSector median 2.9x
Book value₹504.5
Dividend yield–Sector median 0.48%
ROE20.9%Sector median 11.7%
ROCE20.0%Sector median 12.3%
OPM14.1%Sector median 14.0%
Debt / equity0.80xSector median 0.16x
EV/EBITDA8.7xSector median 18.6x
Interest cover2.4x
Current ratio1.68x
Sales growth 3y+32.2%Sector median +9.6%
Profit growth 3y+44.5%Sector median +13.3%
PEG0.38x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹65 cr vs borrowings ₹222 cr (FY26): borrowings are higher by ₹157 cr.
- Operating profit covered interest 2.4x in the last 12 months.
- Other income was 13% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹1,365.50 on 2026-10-26: -18.0% from the 52-week high, +14.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,826.60 · low ₹645.10
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 165 | 119 | 144 | 160 | 210 | 228 |
| EBITDA | 15 | 17 | 21 | 25 | 26 | 32 |
| OPM % | 9.2% | 13.9% | 14.4% | 15.8% | 12.5% | 14.2% |
| Other income | 2 | 0 | 2 | 1 | 3 | 0 |
| Net profit | 6 | 7 | 9 | 10 | 11 | 13 |
| EPS (₹) | 12.71 | 14.33 | 19.98 | 19.53 | 19.70 | 23.82 |
| Revenue YoY | +27.2% | +90.8% | ||||
| Profit YoY | +79.7% | +93.9% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 222 | 274 | 347 | 452 | 633 | 742 |
| EBITDA | 11 | 27 | 36 | 50 | 89 | 104 |
| Net profit | 6 | 11 | 16 | 20 | 33 | 44 |
| EPS (₹) | 14.29 | 22.93 | 33.66 | 44.83 | 66.81 | 83.03 |
| Revenue growth | +23.7% | +26.3% | +30.3% | +40.2% | – | |
| Profit growth | +70.5% | +44.5% | +26.4% | +65.2% | – | |
| Dividend / share (₹) | 0.70 | – | 0.70 | 0.70 | 0.70 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +32.2% | – | – |
| Net profit | +44.5% | – | – |
| EPS | +42.8% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 141 | 278 |
| Borrowings | 167 | 222 |
| Cash & equivalents | 6 | 65 |
| Total assets | 487 | 642 |
| Fixed assets | 52 | 118 |
| Capital work in progress | 0 | – |
| Investments | 1 | 2 |
| Receivables | 177 | 93 |
| Inventory | 240 | 270 |
| Payables | 145 | 88 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -29 | 26 |
| Cash from investing | -6 | -74 |
| Cash from financing | 39 | 121 |
| Capex | 6 | 74 |
| Free cash flow | -35 | -47 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 14.0% | 11.7% |
| ROCE % | 16.2% | 17.2% |
| Debtor days | 143 | 53 |
| Inventory days | 265 | 219 |
| Payable days | 160 | 71 |
| Cash conversion cycle (days) | 248 | 201 |
| Working capital days | 86 | 116 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| FREDUN | ₹753 cr | 16.4x | 2.7x | 20.9% | 20.0% | 14.1% | +32.2% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-06-23 | Dividend | Final Dividend Rs 0.7 |
| 2025-09-23 | Dividend | Final Dividend Rs 0.7 |
| 2024-09-23 | Dividend | Final Dividend Rs 0.7 |
| 2023-09-22 | Dividend | Final Dividend Rs 0.7 |
| 2021-09-16 | Dividend | Final Dividend Rs 0.7 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | FREDUN |
| BSE code | 539730 |
| ISIN | INE194R01017 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.